BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity turns positive
Q1 FY2026 total equity was $372.28M, compared with -$200.03M a year earlier.
Context
- Total equity amounted to 89.1% of total assets at the end of Q1 FY2026, down 44.4 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +286.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 411.1M USD
- Year-over-year change
- +117.8%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 411.1M | +117.8% |
| FY2024 | 2024-12-31 | 188.72M | +296969.0% |
| FY2023 | 2023-12-31 | (63.57K) | -190.6% |
| FY2022 | 2022-12-31 | (21.88K) | -19.2% |
| FY2021 | 2021-12-31 | (18.36K) | — |
Total Equity vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +286.1% is the 2nd highest of 10, against a peer median of +0.4%.
- Total equity amounts to 89.1% of total assets for BBOT, versus a peer median of 69.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $980.17M USD | +512.5% | +11.5% | 94.8% | |
| Aug 2026 | $968.31M USD | +160.1% | +21.1% | 81.0% | |
| Jun 2026 | $503.23M USD | -18.9% | -4.4% | 69.4% | |
SEPNSepterna, Inc. | Sep 2026 | $427.93M USD | +10.1% | — | 69.1% |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $372.28M USD | +286.1% | — | 89.1% |
| Mar 2026 | CHF 196.06M CHF | +20.6% | — | 80.6% | |
| Mar 2026 | $12.75M USD | -62.5% | -47.8% | 3.9% | |
| Sep 2026 | $12.57M USD | -46.9% | -28.8% | 6.0% | |
| Mar 2026 | -$124.25M USD | -167.5% | — | 49.0% | |
| Mar 2026 | -$336.96M USD | +0.4% | — | 110.4% | |
| Peer median (excluding BBOT) | — | +0.4% | -4.4% | 69.4% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.